Reciprocal regulation of miR‐206 and IL‐6/STAT3 pathway mediates IL6‐induced gefitinib resistance in EGFR‐mutant lung cancer cells

Persistently activated IL‐6/STAT3 pathway promotes acquired resistance to targeted therapy with epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) in non–small‐cell lung cancer (NSCLC) treatment. miR‐206 has been verified to be dysregulated and plays as a negative regulator in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yanhua, Wang, Wei, Chang, Hong, Han, Zenglei, Yu, Xinjuan, Zhang, Tingguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815809/
https://www.ncbi.nlm.nih.gov/pubmed/31507089
http://dx.doi.org/10.1111/jcmm.14592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815809/
https://www.ncbi.nlm.nih.gov/pubmed/31507089
http://dx.doi.org/10.1111/jcmm.14592

Ejemplares similares